Spero Therapeutics Inc. (Spero) is a clinical-stage biopharmaceutical company. It develops, identifies and commercializes novel treatments for multi-drug resistant (MDR) bacterial infections. The company's pipeline products include tebipenem HBr, SPR741, SPR206 and SPR720 among others. Its product tebipenem HBr oral gram-negative program, SPR741 and SPR206 IV potentiator platform and SPR720 non-tuberculosis mycobacterium among others. Spero markets its products through third-party distributors. The company markets its products under the brand Spero. It operates in the US. Spero is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
675 Massachusetts Ave Ste 14, Cambridge, 02139-3309
Website
sperotherapeutics.com
Telephone
1 857 2421600
No of Employees
46
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SPRO (NASD)
Revenue (2022)
$103.8M
94%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
149.1%
(2022 vs 2021)
Market Cap*
$77.6M
Net Profit Margin (2022)
XYZ
125.3%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products | Brands |
|---|---|
| Product: | Spero |
| Pipeline products: | |
| SPR720 | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In July, the company, received written agreement from the U.S. Food and Drug Administration (FDA) to design and size of PIVOT-PO, a pivotal Phase 3 clinical trial of tebipenem HBr in patients with complicated urinary tract infection including acute pyelonephritis. |
| 2022 | Contracts/Agreements | In November, the company closed its exclusive license agreement with GlaxoSmithKline Intellectual Property for tebipenem HBr. |
| 2022 | Contracts/Agreements | In September, the company and GSK plc entered into an agreement for tebipenem pivoxil hydrobromide. |
Competitor Comparison
| Key Parameters | Spero Therapeutics Inc | Vertex Pharmaceuticals Inc | Acorda Therapeutics Inc | DURECT Corp | Assertio Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Cambridge | Boston | Pearl River | Cupertino | Lake Forest |
| State/Province | Massachusetts | Massachusetts | New York | California | Illinois |
| No. of Employees | 46 | 5,400 | 102 | 58 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ankit Mahadevia, M.D | Chairman | Executive Board | 2023 | 42 |
| Sath Shukla | Chief Executive Officer; Director; President | Executive Board | 2023 | - |
| Esther Rajavelu | Chief Financial Officer; Chief Business Officer | Senior Management | 2023 | - |
| Timothy Keutzer | Chief Operating Officer | Senior Management | 2023 | 55 |
| Tamara Joseph | Chief Legal Officer | Senior Management | 2020 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer